Zobrazeno 1 - 10
of 202
pro vyhledávání: '"Diane Weber"'
Autor:
Anne E. O'Shea, Guy T. Clifton, Na Qiao, Brandy M. Heckman-Stoddard, Malgorzata Wojtowicz, Eileen Dimond, Isabelle Bedrosian, Diane Weber, Judy E. Garber, Alexander Husband, Ricardo Pastorello, J. Jack Lee, Mike Hernandez, Diane D. Liu, Lana A. Vornik, Powel H. Brown, Gheath Alatrash, George E. Peoples, Elizabeth A. Mittendorf
Publikováno v:
Cancer Prevention Research. :OF1-OF9
NeuVax is a vaccine comprised of the HER2-derived MHC class I peptide E75 (nelipepimut-S, NPS) combined with GM-CSF. We completed a randomized trial of preoperative vaccination with NeuVax versus GM-CSF alone in patients with ductal carcinoma in situ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4d154d04691dbeb3114f4e7e4d82dea9
https://doi.org/10.1158/1940-6207.capr-22-0388
https://doi.org/10.1158/1940-6207.capr-22-0388
Autor:
Elizabeth A. Mittendorf, George E. Peoples, Gheath Alatrash, Powel H. Brown, Lana A. Vornik, Diane D. Liu, Mike Hernandez, J. Jack Lee, Ricardo Pastorello, Alexander Husband, Judy E. Garber, Diane Weber, Isabelle Bedrosian, Eileen Dimond, Malgorzata Wojtowicz, Brandy M. Heckman-Stoddard, Na Qiao, Guy T. Clifton, Anne E. O'Shea
NeuVax is a vaccine comprised of the HER2-derived MHC class I peptide E75 (nelipepimut-S, NPS) combined with GM-CSF. We completed a randomized trial of preoperative vaccination with NeuVax versus GM-CSF alone in patients with ductal carcinoma in situ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f651670fa931553a9dd3bc374ba8183
https://doi.org/10.1158/1940-6207.c.6642622.v1
https://doi.org/10.1158/1940-6207.c.6642622.v1
Autor:
Elizabeth A. Mittendorf, George E. Peoples, Gheath Alatrash, Powel H. Brown, Lana A. Vornik, Diane D. Liu, Mike Hernandez, J. Jack Lee, Ricardo Pastorello, Alexander Husband, Judy E. Garber, Diane Weber, Isabelle Bedrosian, Eileen Dimond, Malgorzata Wojtowicz, Brandy M. Heckman-Stoddard, Na Qiao, Guy T. Clifton, Anne E. O'Shea
Supplementary Table S5: HER2 expression in biopsy and resection specimens
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1943aef419ca844e93810d26a9c95bd6
https://doi.org/10.1158/1940-6207.22806877.v1
https://doi.org/10.1158/1940-6207.22806877.v1
Autor:
Elizabeth A. Mittendorf, George E. Peoples, Gheath Alatrash, Powel H. Brown, Lana A. Vornik, Diane D. Liu, Mike Hernandez, J. Jack Lee, Ricardo Pastorello, Alexander Husband, Judy E. Garber, Diane Weber, Isabelle Bedrosian, Eileen Dimond, Malgorzata Wojtowicz, Brandy M. Heckman-Stoddard, Na Qiao, Guy T. Clifton, Anne E. O'Shea
Supplementary Fig. S2: Nelipepimut-S (NPS)-specific cytotoxic T lymphocyte (CTL) responses in patients receiving GM-CSF alone with corresponding HER2 changes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f5768b15d4693b2055d1127fa9f61cb
https://doi.org/10.1158/1940-6207.22806892
https://doi.org/10.1158/1940-6207.22806892
Autor:
Powel H. Brown, Marjorie Perloff, Brandy M. Heckman-Stoddard, Eileen Dimond, Seema A. Khan, Lana A. Vornik, Diane Weber, Carrie Mays, Valerie Sepeda, Alejandro Contreras, Miguel Muzzio, Mike Hernandez, Diane D. Liu, J. Jack Lee, Anisha B. Patel, Parijatham S. Thomas
Supplementary Table from Phase I Dose Escalation Study of Topical Bexarotene in Women at High Risk for Breast Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::064514fb8344b0af29e094446fbc0a6e
https://doi.org/10.1158/1940-6207.22533313.v1
https://doi.org/10.1158/1940-6207.22533313.v1
Autor:
Powel H. Brown, Marjorie Perloff, Brandy M. Heckman-Stoddard, Eileen Dimond, Seema A. Khan, Lana A. Vornik, Diane Weber, Carrie Mays, Valerie Sepeda, Alejandro Contreras, Miguel Muzzio, Mike Hernandez, Diane D. Liu, J. Jack Lee, Anisha B. Patel, Parijatham S. Thomas
Agents that can reduce the incidence of hormone receptor negative breast cancer are currently lacking. Rexinoids such as bexarotene significantly reduced mammary tumor development in preclinical mouse models. Oral bexarotene in BRCA mutation carriers
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14d02dacc3995a20d4b0470d679d3c74
https://doi.org/10.1158/1940-6207.c.6547021.v1
https://doi.org/10.1158/1940-6207.c.6547021.v1
Autor:
Powel H. Brown, Marjorie Perloff, Brandy M. Heckman-Stoddard, Eileen Dimond, Seema A. Khan, Lana A. Vornik, Diane Weber, Carrie Mays, Valerie Sepeda, Alejandro Contreras, Miguel Muzzio, Mike Hernandez, Diane D. Liu, J. Jack Lee, Anisha B. Patel, Parijatham S. Thomas
Supplementary Table 1: All Adverse Events related to topical 1% bexarotene gel.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ddbf14037926f455c7908eea3e99a4d
https://doi.org/10.1158/1940-6207.22533316.v1
https://doi.org/10.1158/1940-6207.22533316.v1
Autor:
Andrew J. Dannenberg, Powel H. Brown, Clifford A. Hudis, Barbara K. Dunn, Brandy M. Heckman-Stoddard, Patrick G. Morris, Samantha Williams, Margaret Krasne, Holly O'Kane, Valerie Sepeda, Diane Weber, Carrie Mays, Lana A. Vornik, J. Jack Lee, Hanhan Wang, Akanksha Verma, Olivier Elemento, Dilip D. Giri, Priya Bhardwaj, Julie R. Nangia, Katherine D. Crew, Judy E. Garber, Elise D. Cook, Xi K. Zhou, Ayca Gucalp
Clinicopathologic features stratified by treatment arm (RNA-seq analysis population).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a93d9a69a15a36351fbd84e57757cdc
https://doi.org/10.1158/1940-6207.22533553.v1
https://doi.org/10.1158/1940-6207.22533553.v1
Autor:
Davide Serrano, Sara Gandini, Parjhitham Thomas, Katherine D. Crew, Nagi B. Kumar, Lana A. Vornik, J. Jack Lee, Paolo Veronesi, Giuseppe Viale, Aliana Guerrieri-Gonzaga, Matteo Lazzeroni, Harriet Johansson, Mauro D’Amico, Flavio Guasone, Stefano Spinaci, Bjørn-Erik Bertelsen, Gunnar Mellgren, Isabelle Bedrosian, Diane Weber, Tawana Castile, Eileen Dimond, Brandy M. Heckman-Stoddard, Eva Szabo, Powel H. Brown, Andrea DeCensi, Bernardo Bonanni
Publikováno v:
JAMA Oncology. 9:664
ImportanceSuccessful therapeutic cancer prevention requires definition of the minimal effective dose. Aromatase inhibitors decrease breast cancer incidence in high-risk women, but use in prevention and compliance in adjuvant settings are hampered by
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::57e6fe3bcd60281a4ddcb120c07381c3
https://doi.org/10.1001/jamaoncol.2023.0089
https://doi.org/10.1001/jamaoncol.2023.0089
Autor:
Parijatham S. Thomas, Anisha B. Patel, J. Jack Lee, Diane D. Liu, Mike Hernandez, Miguel Muzzio, Alejandro Contreras, Valerie Sepeda, Carrie Mays, Diane Weber, Lana A. Vornik, Seema A. Khan, Eileen Dimond, Brandy M. Heckman-Stoddard, Marjorie Perloff, Powel H. Brown
Publikováno v:
Cancer prevention research (Philadelphia, Pa.). 16(1)
Agents that can reduce the incidence of hormone receptor negative breast cancer are currently lacking. Rexinoids such as bexarotene significantly reduced mammary tumor development in preclinical mouse models. Oral bexarotene in BRCA mutation carriers
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f8e0e50fe655d463b285d4ec69f4d8e2
https://pubmed.ncbi.nlm.nih.gov/36228112
https://pubmed.ncbi.nlm.nih.gov/36228112